急性缺血性卒中血管内治疗围手术期用药的多中心随机临床试验:阿司匹林、普通肝素、两者联用或均不用的研究原理与设计
MR CLEAN-MED 是一项多中心 III 期、前瞻性、2×3 析因随机、开放标签、盲法终点(PROBE)设计的试验,计划纳入 1500 例前循环颅内大血管闭塞的成人卒中患者。试验旨在评估静脉阿司匹林(300 mg)、普通肝素(低或中等剂量)、两者联用或均不用作为血管内治疗辅助治疗对 90 天改良 Rankin 量表(mRS)评分的影响。
要点
- 评估 EVT 围手术期阿司匹林和/或普通肝素对 90 天 mRS 的影响。
- 采用 2×3 析因设计,计划纳入 1500 例前循环大血管闭塞卒中患者。
- 主要结局为 90 天 mRS,采用序数逻辑回归调整主要预后变量。
核心结论
- 尚不确定 EVT 围手术期抗血栓药物能否改善功能结局,阿司匹林和/或普通肝素可能改善结局但增加症状性颅内出血风险。
- 若一种或两种研究治疗显示预期效果,将能改善 EVT 患者结局 5%,在荷兰每年超过 50 例、欧洲超过 1800 例、美国超过 1300 例。
研究设计与样本
- 多中心 III 期、前瞻性、2×3 析因随机、开放标签、盲法终点(PROBE)设计,计划纳入 1500 例患者。
- 纳入临床诊断卒中(NIHSS ≥ 2)且 CTA 或 MRA 证实前循环颅内大血管闭塞、适合且可能在症状发作 6 小时内行 EVT 的成人患者。
- 评估静脉阿司匹林(300 mg)、普通肝素(低或中等剂量)、两者联用或均不用作为 EVT 辅助治疗。
关键数值与推荐
- 主要结局为 90 天改良 Rankin 量表(mRS)评分。
- 采用序数逻辑回归分析 mRS 的治疗效果,并调整主要预后变量。
- 次要结局包括 24 小时和 5-7 天 NIHSS 评分的卒中严重程度、随访梗死体积、症状性颅内出血(sICH)和死亡率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite evidence of a quite large beneficial effect of endovascular treatment (EVT) for ischemic stroke caused by anterior circulation large vessel occlusion, many patients do not recover even after complete recanalization. To some extent, this may be attributable to incomplete microvascular reperfusion, which can possibly be improved by antiplatelet agents and heparin. It is unknown whether periprocedural antithrombotic medication in patients treated with EVT improves functional outcome. The aim of this study is to assess the effect of acetylsalicylic acid (ASA) and unfractionated heparin (UFH), alone, or in combination, given to patients with an ischemic stroke caused by an intracranial large vessel occlusion in the anterior circulation during EVT. METHODS: MR CLEAN-MED is a multicenter phase III trial with a prospective, 2 × 3 factorial randomized, open label, blinded end-point (PROBE) design, which aims to enroll 1500 patients. The trial is designed to evaluate the effect of intravenous ASA (300 mg), UFH (low or moderate dose), both or neither as adjunctive therapy to EVT. We enroll adult patients with a clinical diagnosis of stroke (NIHSS ≥ 2) and with a confirmed intracranial large vessel occlusion in the anterior circulation on CTA or MRA, when EVT within 6 h from symptom onset is indicated and possible. The primary outcome is the score on the modified Rankin Scale (mRS) at 90 days. Treatment effect on the mRS will be estimated with ordinal logistic regression analysis, with adjustment for main prognostic variables. Secondary outcomes include stroke severity measured with the NIHSS at 24 h and at 5-7 days, follow-up infarct volume, symptomatic intracranial hemorrhage (sICH), and mortality. DISCUSSION: Clinical equipoise exists whether antithrombotic medication should be administered during EVT for a large vessel occlusion, as ASA and/or UFH may improve functional outcome, but might also lead to an increased risk of sICH. When one or both of the study treatments show the anticipated effect on outcome, we will be able to improve outcome of patients treated with EVT by 5%. This amounts to more than 50 patients annually in the Netherlands, more than 1800 in Europe, and more than 1300 in the USA. TRIAL REGISTRATION: ISRCT, ISRCTN76741621 . Dec 6, 2017.
引用
- Chalos V, A van de Graaf R, Roozenbeek B, et al. Multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke. The effect of periprocedural medication: acetylsalicylic acid, unfractionated heparin, both, or neither (MR CLEAN-MED). Rationale and study design. Trials. 2020. PMID: 32665035. doi:10.1186/s13063-020-04514-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。